Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Avanza Fonder AB

Avanza Fonder AB decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,702 shares of the medical research company’s stock after selling 2,740 shares during the quarter. Avanza Fonder AB’s holdings in Edwards Lifesciences were worth $4,518,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $610,895,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $75.75 on Wednesday. The stock has a 50 day moving average of $74.12 and a two-hundred day moving average of $72.84. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market capitalization of $44.44 billion, a P/E ratio of 10.87, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.66 EPS. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president now owns 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,153,526.69. This trade represents a 27.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 52,448 shares of company stock worth $3,768,465 in the last 90 days. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Dbs Bank raised Edwards Lifesciences to a “hold” rating in a report on Monday, June 2nd. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Truist Financial reduced their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.